Skip to main content

​New data on use of TIGR® Matrix surgical mesh in Immediate Breast Reconstruction

Press Release   •   Apr 12, 2016 13:28 GMT

New data on use of TIGR® Matrix surgical mesh in Immediate Breast Reconstruction

A new clinical study evaluating the role of TIGR® Matrix in immediate implant-based breast reconstruction has been published ahead of print by the journal Breast Cancer Management.

The study, a single-center, post-procedure investigation, monitored the safety and performance of TIGR® Matrix in adult patients suitable for immediate implant breast reconstruction following skin-sparing mastectomy.

TIGR® Matrix was used in 29 patients undergoing a total of 37 mastectomies and immediate reconstructions. Indications for mastectomy were breast cancer in 29 cases and BRCA 1 or 2 mutations in eight cases.

Early postoperative results showed no adverse reactions to the mesh as well as good tissue integration. The author, Dr Peter Schrenk, Linz, Austria concluded that TIGR® Matrix surgical mesh fulfilled many desired characteristics and requirements for use in implant-based breast reconstruction.

Read more at: www.novusscientific.com/row/schrenk-clin-immediate-breast-recon

About Novus Scientific

Novus Scientific AB (www.novusscientific.com) develops, manufactures and markets resorbable implants that help the body's own healing. Headquarters, research and production are located in Uppsala, Sweden and sales are made through distributors in a growing number of countries, currently around twenty-five.

TIGR® Matrix surgical mesh is a slowly degradable synthetic surgical mesh that contributes mechanical strength until the body itself recreates tissue strength. It is then excreted through natural pathways. TIGR® Matrix is used today in a variety of surgical application areas to reinforce soft tissue where weakness exists.

For more information about TIGR® Matrix, visit: www.tigrmatrix.com